Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-arm, Phase 2/3 Multicentre, Open-label, Randomised Study Evaluating Safety and Antiviral Effect of Current Standard Antiretroviral Therapy Compared to Once Daily Integrase Inhibitor Administered With Darunavir/Ritonavir (DRV/r) in HIV-1 Infected, Virologically Suppressed Paediatric Participants.

NCT02383108 is registered in ClinicalTrials.gov with PENTA Foundation as lead sponsor.

NCT NCT02383108
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02383108 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-arm, Phase 2/3 Multicentre, Open-label, Randomised Study Evaluating Safety and Antiviral Effect of Current Standard Antiretroviral Therapy Compared to Once Daily Integrase Inhibitor Administered With Darunavir/Ritonavir (DRV/r) in HIV-1 Infected, Virologically Suppressed Paediatric Participants.
Lead sponsor
PENTA Foundation
Phase
Phase 2/3
Overall status
Completed
Start date
June 30, 2016
Completion date
October 31, 2020
Enrollment
318 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infection